Medications known as GLP-1 inhibitors have made headlines in recent years due to their effectiveness in managing blood sugar ...

A new weight-loss drug candidate combines four hormone targets—GLP-1, GIP, glucagon, and peptide YY (PYY)—to enhance appetite suppression and energy expenditure.

This effect is partly caused by protein’s effect on the hormones glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), and peptide YY (PYY), which signal satiety and reduce overall calorie ...

Their aim was to find a natural compound that impacted L-cells, which secrete glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), two key hormones in hunger satiety, metabolism and blood sugar ...

Gram-scale synthesis was achieved on a recombinantly prepared peptide YY analogue. This flow reaction demonstrates the potential for amidated drug leads to enter development that would not be viable ...